<DOC>
	<DOC>NCT02792998</DOC>
	<brief_summary>The objectives of this study are: Stage 1: To assess the safety, tolerability, pharmacokinetic (PK) profile and pharmacodynamic (PD) effects of a range of doses of IW-1701 tablets administered orally to healthy subjects over 7 days of repeated dosing Stage 2: To assess the safety, tolerability, PK profile and PD effects of IW-1701 tablets administered orally to healthy subjects, in fed and fasted states, in an open-label, single-dose, 2-period, 2-sequence crossover study.</brief_summary>
	<brief_title>A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Subject is an ambulatory male or female between 18 and 55 years old at the screening visit Subject's body mass index score is &gt; 18.5 and &lt; 30.0 kg/m2 at the screening visit Women of childbearing potential must have a negative pregnancy test at the time of checkin and must agree to use doublebarrier contraception throughout the duration of the study Subject is in good health and has no clinically significant findings on a physical examination Other inclusion criteria per protocol History of any clinically significant medical conditions Other exclusion criteria per protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>